Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
出版年份 2015 全文链接
标题
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
作者
关键词
-
出版物
Scientific Reports
Volume 5, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-02-03
DOI
10.1038/srep08202
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells
- (2015) Florian Rothweiler et al. NEOPLASIA
- Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer
- (2013) Peter Nygren et al. ACTA ONCOLOGICA
- Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines
- (2013) Věra Králová et al. ANTI-CANCER DRUGS
- Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
- (2013) Peter Nygren et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Chemotherapy-Associated Angiogenesis in Neuroblastoma Tumors
- (2012) Martin Michaelis et al. AMERICAN JOURNAL OF PATHOLOGY
- Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution
- (2012) Laura Ceballos et al. BMC Veterinary Research
- Predicting New Indications for Approved Drugs Using a Proteochemometric Method
- (2012) Sivanesan Dakshanamurthy et al. JOURNAL OF MEDICINAL CHEMISTRY
- The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses
- (2011) F Durupt et al. CANCER GENE THERAPY
- Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
- (2011) Irina Dobrosotskaya et al. Endocrine Practice
- Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- (2011) Ren-Yuan Bai et al. NEURO-ONCOLOGY
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
- (2011) M Michaelis et al. Cell Death & Disease
- The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
- (2010) P. A. Spagnuolo et al. BLOOD
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
- (2010) J. Carr-Wilkinson et al. CLINICAL CANCER RESEARCH
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Recent Advances in Neuroblastoma
- (2010) John M. Maris NEW ENGLAND JOURNAL OF MEDICINE
- Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer
- (2009) Mohammad H. Pourgholami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
- (2009) M. Michaelis et al. CANCER RESEARCH
- Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis
- (2009) K Weber et al. GENE THERAPY
- Flubendazole in cystic echinococcosis therapy: Pharmaco-parasitological evaluation in mice
- (2009) Laura Ceballos et al. PARASITOLOGY INTERNATIONAL
- Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
- (2008) E. A. Bassett et al. CLINICAL CANCER RESEARCH
- The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
- (2008) Gergely Szakács et al. DRUG DISCOVERY TODAY
- Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
- (2008) N. Doudican et al. MOLECULAR CANCER RESEARCH
- A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis
- (2008) Kristoffer Weber et al. MOLECULAR THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started